Vertex Pharmaceuticals (VRTX) Operating Leases (2018 - 2026)

Vertex Pharmaceuticals has reported Operating Leases for 9 years, with the latest figure at $2.0 billion in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases rose 29.19% year-over-year to $2.0 billion; the trailing twelve-month figure through Mar 2026 stood at $2.0 billion (up 29.19% YoY), and the FY2025 full-year result was $1.8 billion, up 19.56% from the prior year.
• Operating Leases for Q1 2026 stood at $2.0 billion, up from $1.8 billion in the prior quarter.
• The five-year high for Operating Leases was $2.0 billion in Q1 2026, with the low at $348.6 million in Q4 2023.
• Average Operating Leases over 5 years is $929.6 million, with a median of $428.1 million recorded in 2022.
• Year-over-year, Operating Leases retreated 18.57% in 2023 and surged 348.34% in 2024.
• Tracing VRTX's Operating Leases over 5 years: stood at $428.1 million in 2022, then decreased by 18.57% to $348.6 million in 2023, then jumped by 343.03% to $1.5 billion in 2024, then climbed by 19.56% to $1.8 billion in 2025, then rose by 7.58% to $2.0 billion in 2026.
• The last three Operating Leases figures came in at $2.0 billion (Q1 2026), $1.8 billion (Q4 2025), and $1.8 billion (Q3 2025), per Business Quant data.

Peer Comparison